QIAGEN updates proposal to acquire Cellestis
Cellestis board of directors unanimously support amended proposal offering its shareholders a 7% increase to A$3.80 per share from original offer of A$3.55
14-Jul-2011 -
QIAGEN N.V. announced that it has amended its original proposal to acquire Cellestis Limited, a publicly traded Australian biotechnology company.Under terms of the amended proposal, the per-share offer price is being increased by 7% to A$3.80 from the original offer price of A$3.55 announced on ...
biotechnology
Qiagen